BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Naproxen nanoformulation: Phase I data

A crossover Phase I trial in 40 healthy volunteers showed that a single 400 mg dose of naproxen formulated with SoluMatrix nanoformulation technology from partner iCeutica Inc....

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >